Cargando…
Immunotherapy in non-small cell lung cancer: Update and new insights
BACKGROUND: The treatment of non-small-cell lung carcinoma (NSCLC) has changed markedly in recent years as a result of two major treatment milestones: Targeted therapy and immunotherapy. Since 2015, immunotherapy has been changing the paradigm of NSCLC treatment in different settings and has contrib...
Autores principales: | Mielgo-Rubio, Xabier, Uribelarrea, Eider Azkona, Cortés, Laura Quintanta, Moyano, María Sereno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Whioce Publishing Pte. Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177026/ https://www.ncbi.nlm.nih.gov/pubmed/34104805 |
Ejemplares similares
-
Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer
por: Sereno, María, et al.
Publicado: (2021) -
Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast
por: Aguado, Carlos, et al.
Publicado: (2022) -
High tumor burden in non-small-cell lung cancer: A review of the literature
por: Cabezón-Gutiérrez, Luis, et al.
Publicado: (2022) -
Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy
por: Aguado, Carlos, et al.
Publicado: (2022) -
Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2021)